Latest news with #EyePointPharmaceuticals
Business Insider
29-05-2025
- Business
- Business Insider
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) today and set a price target of $26.00. The company's shares closed today at $7.04. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Apellis Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -9.0% and a 37.69% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $31.57 average price target, a 348.44% upside from current levels. In a report released today, Scotiabank also reiterated a Buy rating on the stock with a $18.00 price target. Based on EyePoint Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.45 million and a GAAP net loss of $45.2 million. In comparison, last year the company earned a revenue of $11.68 million and had a GAAP net loss of $29.28 million Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year. Earlier this month, Karen Zaderej, a Director at EYPT bought 10,000.00 shares for a total of $59,000.00.
Yahoo
28-05-2025
- Business
- Yahoo
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 1:25 p.m. ET Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Tuesday, June 10, 2025Time: 2:40 p.m. ET Guggenheim BioFrontier Boston EventDate: Wednesday, June 25, 2025Time: 4:00 p.m. ET A live webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-scale manufacturing facility in Northbridge, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Investors: Tanner Kaufman / Jenni LuFTI Consulting Direct: 203-722-8743 / / Media Contact: Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@
Yahoo
16-05-2025
- Business
- Yahoo
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 136,700 shares of EyePoint common stock to seven new employees. The stock options were granted on May 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $5.72 per share, the closing price of EyePoint's common stock on May 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint through the applicable vesting dates. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-ready manufacturing facility in Northbridge, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. For EyePoint: Investors:Christina TartagliaPrecision AQDirect: Media Contact:Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
07-05-2025
- Business
- Washington Post
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
WATERTOWN, Mass. — WATERTOWN, Mass. — EyePoint Pharmaceuticals (EYPT) on Wednesday reported a loss of $45.2 million in its first quarter. The Watertown, Massachusetts-based company said it had a loss of 65 cents per share.
Yahoo
06-03-2025
- Business
- Yahoo
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k
Some of the losses seen by insiders who purchased US$184.5k worth of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shares over the past year were recovered after the stock increased by 12% over the past week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$32k. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether. See our latest analysis for EyePoint Pharmaceuticals In the last twelve months, the biggest single purchase by an insider was when Independent Director Karen Zaderej bought US$100k worth of shares at a price of US$7.98 per share. That means that an insider was happy to buy shares at above the current price of US$6.58. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Happily, we note that in the last year insiders paid US$185k for 23.24k shares. But they sold 5.55k shares for US$61k. Overall, EyePoint Pharmaceuticals insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! EyePoint Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests EyePoint Pharmaceuticals insiders own 0.9% of the company, worth about US$4.0m. We consider this fairly low insider ownership. It doesn't really mean much that no insider has traded EyePoint Pharmaceuticals shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if EyePoint Pharmaceuticals insiders bought more shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that EyePoint Pharmaceuticals is showing 3 warning signs in our investment analysis, and 1 of those is concerning... But note: EyePoint Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
